Longeveron Inc. — Third Quarter 2026 Earnings Summary

Longeveron Inc. reported a net loss of $6.1 million for the third quarter ended September 30, 2026, driven by research and development expenses of $4.0 million and general and administrative costs of $3.3 million. The company's Phase 2b ELPIS II clinical trial for hypoplastic left heart syndrome did not meet its primary efficacy endpoint, prompting a request for a meeting with the FDA to determine future development steps. Concurrently, Longeveron is evaluating strategic alternatives, including potential partnerships, mergers, or sales, with Lucid Capital Markets retained as financial advisor to maximize stockholder value. The company implemented a 1-for-10 reverse stock split in August and currently holds $7.2 million in cash, which is expected to fund operations into the first quarter of 2027.